Anavex Life Sciences Corp (AVXL)

[Investor2014]

This is an example of why in biotech investing one shouldn't just eat raw the highlights of data and its interpretation that a company publishes.

Confirmed dose-response:
RS-001 study 5mg ANAVEX®2-73 dose RSBQ AUC Cohen’s d (effect size) of 0.517.
RS-002 study 30mg ANAVEX®2-73 dose RSBQ AUC Cohen’s d (effect size) of 1.91.

Often there is more detail to it and sometimes the devil is in those detail.

One such detail here is that there were only 3 sample point, one at baseline, another at 4 weeks and the last at 7 weeks.

What would more samples look like say once per week - linear improvement or all over the place? What effect might that have on the published results?